Taylor Wessing advises Oxford BioMedica on global licensing agreement with sanofi-aventis

30-Mar-2007  |  Corporate, Life Sciences & Healthcare

CLIENT

Oxford BioMedica

VALUE

€518 million (~US$690 million)

TRANSACTION

Global licensing agreement

DESCRIPTION

Taylor Wessing advised Oxford BioMedica (LSE: OXB) and sanofi-aventis (EURONEXT: SAN; NYSE: SNY) on an exclusive global licensing agreement to develop and commercialise TroVax® for the treatment and prevention of cancers.